Karadeniz Technical University, Faculty of Medicine, Farabi Hospital
Trabzon, 61080, Turkey (Türkiye)
NCT Number: NCT05280665
Specialization is having competent and effective knowledge on a subject, and the tendency towards specialization is increasing due to the fact that it increases the success in the follow-up and treatment process of diseases. It has been observed that specialization in cancer surgery provides significant improvement in clinical outcomes in recent years. In this study, the effect of specialization in gastric cancer surgery on clinical outcomes is being investigated.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Trabzon, 61080, Turkey (Türkiye)
Specialization is having sufficient and effective knowledge on a subject. Today, in the medical world, specialization is defined as having competent knowledge on a disease, and in recent years, the benefit of specialization has begun to be emphasized. Initially, it was defined as a branching and over the years, internal and surgical departments were divided into sub-areas. In surgical sciences, these fields are determined as traumatology, breast-endocrine surgery and gastrointestinal system surgery. This branching has brought a different perspective and approach to diseases and has made it possible to be more effective in the management of diseases. In recent years, a specialization approach on diseases and organ systems has developed within these branches. In surgery, surgeons specialized on many organs such as pancreatic surgery, colorectal surgery, gastric surgery, breast surgery, ovarian surgery have increased the efficiency in the management of diseases and the survival and disease-free survival rates of the patients have increased, and the postoperative morbidity and mortality rates have decreased.
Gastric cancer is one of the most common malignant cancers. It is the fifth most common cause of cancer-related death worldwide. Despite advances in diagnosis and treatment methods, patients may still be diagnosed late, and patients still have a poor prognosis due to the biology of gastric cancer. Even in properly treated patients, five-year survival rates are around 20-30%. With the development of surgical techniques and disease management, clinical outcomes of the disease have improved and mortality has been reduced. In the studies, the definition of gastric surgeon was created and it was determined that the mortality decreased proportionally with the increase in the patient volume of the surgeon. In gastric cancer surgery, there are mostly studies on the number of surgeon patients and the number of hospital patients. Post-hoc analysis of hospital volume on patients included in the CRITICS study showed a 13.1% increase in survival in high-volume hospitals compared to low-volume hospitals. The number of annual resections ≥21 was determined as the definition of high-volume hospital. In addition, it was determined that there was a decrease in mortality as the number of annual cases increased in high-volume hospitals. In another study, it was seen that there was an improvement in the mortality of medium and high volume hospitals compared to low volume hospitals. The majority of studies in gastric cancer surgery have focused on hospital volume and surgeon volume. There are no data on the specialization of the surgeon other than a study based in Japan.
In this study, it was aimed to evaluate the effect of specialization in gastric cancer surgery on short- and long-term clinical outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Gastric cancer surgery
Time frame: 30 days after the operation (postoperative hospital stay ≤ 30 days) or operation to first discharge from hospital (postoperative hospital stay > 30 days)
Death from any cause within 30 days after surgery or at any time if not discharged from hospital
Time frame: 90 days after the operation (postoperative hospital stay ≤ 90 days) or operation to first discharge from hospital (postoperative hospital stay > 90 days)
Death from any cause within 90 days after surgery or at any time if not discharged from hospital
Time frame: Within 30 days after the operation
Any complications (graded by the Clavien-Dindo classification) occurred in the postoperative period
Time frame: Within 30 days after the operation
≥grade-III Clavien-Dindo complications occurred in the postoperative period
Time frame: Within 30 days after the operation
Readmission requiring re-hospitalization for any complications after discharge
Time frame: 3 years after surgery
Death from any cause is defined as an event.
Time frame: 3 years after surgery
Death from any cause or the recurrence of gastric cancer are an event.
Time frame: From the date of surgery until the date of hospital discharge, assessed up to 90 days after the operation
Duration of postoperative hospital stays
Time frame: Within 30 days after the operation
futile surgery due to intraoperative distant metastasis/irresectability, OR microscopically or macroscopically incomplete resection OR 30-day mortality
Time frame: Within the three months before surgery
Neoadjuvant treatment usage rates in patients undergoing surgical treatment
Karadeniz Technical University
Other
The Impact of Specialization on Clinical Outcomes in Gastric Cancer Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01614522
Cancer of Stomach, Cancer of the Stomach
Bundang, Seoul, South Korea
View Trial DetailsNCT07183358
Digestive System Diseases, Digestive System Neoplasms
Qingdao, Shandong, China
View Trial DetailsNCT06451211
Digestive System Diseases, Digestive System Neoplasms
Guangzhou, Guangdong, China
View Trial DetailsNCT07682220
Behavior, Digestive System Diseases
Harbin, Heilongjiang, China
View Trial Details